Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Wiener Klinische Wochenschrift|September 16, 2021
Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter studySabine Geiger-Gritsch, Horst Olschewski, Florian Kocher, et al.Virchows Archiv : an International Journal of Pathology|March 10, 2018
Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lungLuka Brcic, Stefanie Stanzer, Dagmar Krenbek, et al.Journal for Immunotherapy of Cancer|April 11, 2024
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLCNikolaus John, Verena Schlintl, Teresa Sassmann, et al.Plos One|November 14, 2013
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patientsJoanna Szkandera, Michael Stotz, Florian Eisner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2018
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLCAnna Buder, Maximilian J Hochmair, Sophia Schwab, et al.Cancers|July 14, 2023
Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer TypesIrina Robinson, Maximilian Johannes Hochmair, Manuela Schmidinger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancerArmin Gerger, Anthony El-Khoueiry, Wu Zhang, et al.Pharmaceuticals (Basel, Switzerland)|November 11, 2020
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter AnalysisMaximilian J Hochmair, Hannah Fabikan, Oliver Illini, et al.Cancer Medicine|March 17, 2022
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer studyDominik A Barth, Stefanie Stanzer, Jasmin Spiegelberg, et al.Cancers|August 23, 2020
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center StudyJakob M Riedl, Dominik A Barth, Wolfgang M Brueckl, et al.Pageof 4